Skip to main content
OpenTrials
Completed

NCT Number: NCT05329428

PREDIN: Pregnancy and Vitamin D Intervention Study

Vitamin D deficiency is common among certain risk groups in Sweden, and occurs approximately in every tenth pregnant woman.The aim of the randomized double-blind controlled trial Pregnancy vitamin D intervention (PREDIN) is to investigate the dose of vitamin D supplementation required in achieving vitamin D sufficiency (25OHD ≥50 nmol/l) in pregnant women at risk of vitamin D deficiency. In addition, the investigators aim to examine if the overall vitamin D status and vitamin D intake have increased since the expanded vitamin D fortification program was initiated in year 2020.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Antenatal Care

Gothenburg, Sweden

About this study

The effect of maternal vitamin D in pregnancy for maternal and offspring health needs to be clarified. In observational studies, the investigators and others show associations between poor maternal vitamin D status in pregnancy and an increased risk of pregnancy complications. Poor maternal vitamin D status is also linked to impaired growth in the first year of life, and potentially also to higher risk of developing obesity in childhood. Risk factors for vitamin D deficiency in Swedish pregnant women are related to lower intake of vitamin D and to less sun exposure.

Since the evidence for positive effects of maternal vitamin D status or intake is limited, vitamin D interventions in pregnancy are warranted to clarify the causal effects of vitamin D in pregnancy and the doses required to achieve sufficient vitamin D status in deficient women. In the first trimester, pregnant women will be screened at a routine visit in the antenatal care for the risk of vitamin D deficiency using a validated questionnaire. Women who are classified as having a high risk of vitamin D deficiency will be randomized to one of three study arms: usual antenatal care, 20 µg vitamin D per day or 40 µg vitamin D per day. The participants will be followed up until delivery. Blood will be collected for analysis of vitamin D status (25OHD) at screening and in the third trimester of pregnancy. Information regarding pregnancy, gestational complication and fetal growth will be retrieved from medical records after delivery. About 500 women will be screened and their vitamin D status and vitamin D intake will be compared to a previous population-based cohort study, to investigate if the status or intake of vitamin D has increased since the expanded food fortification program was introduced.

The study hypothesis is that vitamin D status and/or vitamin D intake is related to risk of developing complications during pregnancy or delivery and that maternal supplementation with vitamin D during pregnancy will be effective in achieving vitamin D sufficiency in pregnant women at risk of vitamin D deficiency. In addition, the investigators hypothesize that the expanded vitamin D food fortification program has increased the vitamin D status and vitamin D intake of pregnant women in Gothenburg since 2013-2014.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • pregnant women in gestational week <15

Exclusion criteria

  • multi-fetal pregnancy
  • known disorder to the metabolism of vitamin D, calcium or phosphate (e.g. adrenal gland disorders, kidney disease)
  • ongoing treatment with vitamin D of ≥10 µg/day
  • difficulties understanding the study information

Treatment and study plan

Vitamin D Supplementation 20 µg/day

Dietary Supplement

At a routine visit at the antenatal care in early pregnancy (gestational week <15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.

Vitamin D Supplementation 40 µg/day

Dietary Supplement

At a routine visit at the antenatal care in early pregnancy (gestational week <15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.

Usual Antenatal Care

Other

In early pregnancy (gestational week <15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.

Primary outcomes

  1. Difference in maternal vitamin D status (25OHD) between intake of vitamin D supplements containing either 40 µg per day or 20 µg per day during pregnancy

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of 25OHD (25OHD3 and 25OHD2) from blood samples drawn in first- and third trimester of pregnancy

  2. Difference in maternal vitamin D status (25OHD) between intake of vitamin D supplements (both 40 µg per day or 20 µg per day) during pregnancy and usual antenatal care routines

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of 25OHD (25OHD3 and 25OHD2) from blood samples drawn in first- and third trimester of pregnancy

  3. Difference in maternal 3-epi-25-Hydroxyvitamin D between the three groups; intakes of vitamin D supplements 40 µg/day or 20 µg/day or usual antenatal care routines

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of vitamin D metabolites 3-epi-25-Hydroxyvitamin D3 from blood samples drawn in first- and third trimester of pregnancy

  4. Difference in maternal 1,25-dihydroxyvitamin D between the three groups; intakes of vitamin D supplements 40 µg/day or 20 µg/day or usual antenatal care routines

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of 1,25-dihydroxyvitamin D from blood samples drawn in first- and third trimester of pregnancy

  5. Difference in maternal vitamin D binding proteins between the three groups; intakes of vitamin D supplements 40 µg/day or 20 µg/day or usual antenatal care routines

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of vitamin D binding proteins from blood samples drawn in first- and third trimester of pregnancy

Secondary outcomes

  1. Gene variant related to vitamin D metabolism

    Time frame: At inclusion in first trimester of pregnancy

    Analyses of gene variants in blood sample drawn at inclusion in first trimester of pregnancy

  2. Ferritin

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of ferritin

  3. Hemoglobin

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of hemoglobin

  4. Metabolomics

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of metabolomics in blood

  5. C-reactive protein

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of inflammation e.g. c-reactive protein

  6. Interleukines

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of inflammation e.g. interleukines

  7. Cytokines

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of inflammation e.g. cytokines

  8. Cortisol

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of cortisol

  9. Parathyroid hormone

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analysis of parathyroid hormone in sampled blood at the routine laboratory

  10. Estrogen

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of estrogen, in sampled blood, at the routine laboratory

  11. Progesterone

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of progesterone, in sampled blood, at the routine laboratory

  12. 24,25-Dihydroxyvitamin D

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Analyses of 24,25(OH)2D (24,25(OH)2D3 and 24,25(OH)2D2)

  13. Dietary intake

    Time frame: At inclusion in first trimester and at follow-up in third trimester, up to 9 months

    Dietary intake of mother during pregnancy assessed by dietary record at two time points

  14. Body weight development

    Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months

    Self-reported weight (in kilograms) during pregnancy until delivery.

  15. Incidence of pregnancy-induced hypertension

    Time frame: Up to delivery

    Diagnosis of pregnancy-induced hypertension

  16. Incidence of pre-eclampsia

    Time frame: Up to delivery

    Diagnosis of pre-eclampsia

  17. Incidence of gestational diabetes

    Time frame: Up to delivery (up to 9 months)

    Diagnosis of gestational diabetes

  18. Incidence of preterm delivery

    Time frame: Up to 37 completed weeks

    Delivery before 37 weeks completed weeks of gestation

  19. Incidence of small for gestational age (SGA)

    Time frame: At delivery

    SGA born infant

  20. Incidence of large for gestational age (LGA)

    Time frame: At delivery

    LGA born infant

  21. Incidence of Intrauterine growth restriction (IUGR)

    Time frame: At delivery

    IUGR

  22. Apgar scores

    Time frame: At 1, 5 and 10 minutes after delivery

    Vitality signs are estimated as Apgar scores at 1, 5 and 10 minutes after birth of the newborn. Apgar stands for Appearance, pulse, grimace, activity and respiration. The maximium score at each time point is 10 scores and a high score indicates high vitality, where as a low score indicates very low vitality.

  23. Incidence of Caesarean sections

    Time frame: At delivery

    Delivery by caesarean sections

  24. Incidence of miscarriage

    Time frame: During the first 21+6 weeks of pregnancy

    Miscarriage

  25. Incidence of Intrauterine fetal demise (IUFD)

    Time frame: Any time during pregnancy after pregnancy week 22+0 (up to 9 months)

    IUFD

Sponsors and collaborators

Lead sponsor

Göteborg University

Other

Collaborators

  • Vastra Gotaland Region

Registry information

Official study title

PREDIN: Pregnancy and Vitamin D Intervention Study - A Randomized Controlled Trial

Acronym: PREDIN

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Apr 15, 2022
Registry last updated
Mar 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.